Literature DB >> 32791064

Well-differentiated liposarcoma primary from thymic stroma: Case report and literature review.

Karina Furlan1, Ira Miller2, Prih Rohra2, Fatima Mir2, Fernando A Ocampo Gonzalez2, Paolo Gattuso2.   

Abstract

Primary liposarcoma of thymic stroma is an exceptionally rare tumor. Histological findings are often definitive for diagnosis, however due to the variability of nuclear atypia and the overlapping with other adipocytic tumors, ancillary techniques are helpful as confirmatory tools. Currently, Fluorescent in situ hybridization for MDM2 is the gold standard for diagnosis of well-differentiated and dedifferentiated liposarcomas, however a panel of immunohistochemical stainings, including MDM2, CDK4 and p16 is available as alternative method, helping to distinguish liposarcoma from its benign counterpart lipoma, especially in borderline cases. We describe the case of a young female diagnosed with a well-differentiated lipomatous tumor primary of thymic stroma with near cut-off result for MDM2-FISHand positive immunohistochemical staining for the panel described above. We discuss the challenges in the diagnosis of this rare entity andpresent an updated literature review.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liposarcoma; MDM2; Mediastinum; Thymus

Mesh:

Substances:

Year:  2020        PMID: 32791064     DOI: 10.1016/j.yexmp.2020.104517

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  2 in total

1.  A giant tumor of the mediastinum mixed with thymocytes and adipocytes: a case report.

Authors:  Hui Wang; Qiao Li; Qichang Jiang; Yanmiao Yang; Yang Liu; Longfeng Gu; Ming Gong; Gang Xu; Cheng Chen
Journal:  Gland Surg       Date:  2021-11

2.  Primary intrathoracic liposarcomas: A clinicopathologic and molecular study of 43 cases in one of the largest medical centers of China.

Authors:  You Xie; Wenyi Jing; Wei Zhao; Ran Peng; Min Chen; Ting Lan; Heng Peng; Xin He; Huijiao Chen; Zhang Zhang; Hongying Zhang
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.